$1.41
+0.01 (+0.71%)
Open$1.40
Previous Close$1.40
Day High$1.43
Day Low$1.38
52W High$8.08
52W Low$1.01
Volume—
Avg Volume637.4K
Market Cap39.37M
P/E Ratio—
EPS$-5.74
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,457.4% upside
Current
$1.41
$1.41
Target
$21.96
$21.96
$14.05
$21.96 avg
$26.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.58M | 1.33M | 5.52M |
| Net Income | -172,066,336 | -130,024,939 | -589,967 |
| Profit Margin | -10,887.4% | -10,343.0% | -10.7% |
| EBITDA | -123,483,253 | -98,496,297 | -924,468 |
| Free Cash Flow | — | — | -774,673 |
| Rev Growth | +19.1% | +19.1% | -1.7% |
| Debt/Equity | 1.21 | 1.21 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |